Both medications can cause side effects, especially when starting treatment or increasing the dose
Allergic Reactions: Although rare, serious allergic reactions can occur, with symptoms such as swelling of the face, lips, tongue, or throat, difficulty breathing or swallowing, rapid heartbeat, fainting, or severe rash
The compound is designed for subcutaneous injection, typically administered in the abdomen, thigh, or upper arm, following the same injection site recommendations used for other GLP-1 agonists
Mounjaro has been authorised for use in the EU since 15 September 2022, so a licensed doctor can prescribe it when it is clinically appropriate for you